Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Express Scripts
Mallinckrodt
AstraZeneca
Boehringer Ingelheim

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Sofosbuvir; Velpatasvir; Voxilaprevir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02185794 ↗ Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection Completed Gilead Sciences Phase 1 2014-06-13 The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir in adults with genotype 1, 2, 3, 4 hepatitis C virus (HCV) infection. All participants will be monitored for up to 48 weeks after the last dose.
NCT02378935 ↗ Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection Completed Gilead Sciences Phase 2 2015-02-17 This primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) ┬▒ ribavirin (RBV) in adults with chronic genotype 1 hepatitis C virus (HCV) infection.
NCT02378961 ↗ Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection Completed Gilead Sciences Phase 2 2015-02-16 The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) in adults with chronic non genotype 1 hepatitis C virus (HCV) infection.
NCT02533427 ↗ Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol Completed Gilead Sciences Phase 1 2015-10-29 This study will evaluate the effect of sofosbuvir (SOF)/velpatasvir (VEL)/voxilaprevir (VOX) fixed-dose combination (FDC) + voxilaprevir on the pharmacokinetics (PK) of a representative hormonal contraceptive medication, norgestimate/ethinyl estradiol (Ortho Tri-Cyclen┬« Lo (OC)) and will assess the effect of norgestimate/ethinyl estradiol on the PK of SOF/VEL/VOX+VOX.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sofosbuvir; Velpatasvir; Voxilaprevir

Condition Name

Condition Name for Sofosbuvir; Velpatasvir; Voxilaprevir
Intervention Trials
Hepatitis C Virus Infection 9
Hepatitis C 4
Chronic Hepatitis C 2
Cirrhosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sofosbuvir; Velpatasvir; Voxilaprevir
Intervention Trials
Hepatitis C 17
Infections 10
Infection 10
Virus Diseases 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sofosbuvir; Velpatasvir; Voxilaprevir

Trials by Country

Trials by Country for Sofosbuvir; Velpatasvir; Voxilaprevir
Location Trials
United States 144
Australia 16
Canada 15
New Zealand 10
Puerto Rico 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sofosbuvir; Velpatasvir; Voxilaprevir
Location Trials
Florida 8
California 8
Texas 8
Tennessee 8
Pennsylvania 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sofosbuvir; Velpatasvir; Voxilaprevir

Clinical Trial Phase

Clinical Trial Phase for Sofosbuvir; Velpatasvir; Voxilaprevir
Clinical Trial Phase Trials
Phase 4 5
Phase 3 6
Phase 2 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sofosbuvir; Velpatasvir; Voxilaprevir
Clinical Trial Phase Trials
Completed 13
Recruiting 2
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sofosbuvir; Velpatasvir; Voxilaprevir

Sponsor Name

Sponsor Name for Sofosbuvir; Velpatasvir; Voxilaprevir
Sponsor Trials
Gilead Sciences 13
Unity Health Care, Inc. 1
University of Maryland 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sofosbuvir; Velpatasvir; Voxilaprevir
Sponsor Trials
Industry 14
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
McKinsey
Express Scripts
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.